Compounds > 3,4-dihydroxyphenylacetaldehyde
Page last updated: 2024-09-03

3,4-dihydroxyphenylacetaldehyde and alpha-synuclein

3,4-dihydroxyphenylacetaldehyde has been researched along with alpha-synuclein in 19 studies

Compound Research Comparison

Studies
(3,4-dihydroxyphenylacetaldehyde)		Trials
(3,4-dihydroxyphenylacetaldehyde)		Recent Studies (post-2010)
(3,4-dihydroxyphenylacetaldehyde)		Studies
(alpha-synuclein)		Trials
(alpha-synuclein)		Recent Studies (post-2010) (alpha-synuclein)
9905010,821298,011

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (5.26)29.6817
2010's15 (78.95)24.3611
2020's3 (15.79)2.80

Authors

AuthorsStudies
Galvin, JE1
Cooney, A; Goldstein, DS; Gross, D; Jinsmaa, Y; Sharabi, Y; Sullivan, P1
Goldstein, DS; Kopin, IJ; Sharabi, Y1
Cooney, A; Goldstein, DS; Jinsmaa, Y; Sharabi, Y; Sullivan, P1
Araujo, GD; Coelho-Cerqueira, E; Domont, GB; Eliezer, D; Follmer, C; Pinheiro, AS; Yatabe-Franco, DY1
Bubacco, L; Plotegher, N1
Goldstein, DS; Jinsmaa, Y; Sharabi, Y; Sullivan, P1
Bax, A; DuMond, JF; Levine, RL; Werner-Allen, JW1
Berti, G; Bisaglia, M; Bubacco, L; Casella, L; Dalla Serra, M; Ferrari, E; Girotto, S; Greggio, E; Lunelli, L; Perego, C; Plotegher, N; Tessari, I; Veronesi, M; Zanetti, M1
Bax, A; Levine, RL; Werner-Allen, JW1
Diwakar, S; Melethadathil, N; Nair, B; Sasidharakurup, H1
Goldstein, DS; Sharabi, Y1
Bellen, HJ; Chen, R; D'Amelio, M; Gibbs, RA; Goldstein, DS; Graham, BH; Landrock, KK; Martini-Stoica, H; Stoica, G; Sullivan, P; Yamamoto, S1
Bax, A; DuMond, JF; Levine, RL; Monti, S; Werner-Allen, JW1
do Nascimento, LA; Eliezer, D; Follmer, C; Lima, VA1
Burke, WJ; Gillespie, KN; Hsu, FF; Kumar, VB; Lakshmi, VM1
Goldstein, DS; Isonaka, R; Jinsmaa, Y; Sharabi, Y1
Cui, CP; Feng, Y; Gao, S; He, C; Li, BY; Li, KX; Qiao, GF; Sun, J; Sun, X; Wang, HD; Wang, X; Xiong, X; Yan, QX; Yin, RX; Zha, RR1
Acquasaliente, L; Bucciantini, M; Fongaro, B; Leri, M; Palazzi, L; Polverino de Laureto, P; Stefani, M1

Reviews

4 review(s) available for 3,4-dihydroxyphenylacetaldehyde and alpha-synuclein

ArticleYear
Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
    Acta neuropathologica, 2006, Volume: 112, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Dopamine; Humans; Oxidative Stress; Parkinson Disease; Substantia Nigra

2006
Catecholamine autotoxicity. Implications for pharmacology and therapeutics of Parkinson disease and related disorders.
    Pharmacology & therapeutics, 2014, Volume: 144, Issue:3

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Apoptosis; Catecholamines; Humans; Lipid Peroxidation; Neurodegenerative Diseases; Neurons; Oxidation-Reduction; Parkinson Disease

2014
Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin.
    Ageing research reviews, 2016, Volume: 26

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Brain; Dopamine; Humans; Lysine; Metabolism; Neurodegenerative Diseases; Neurons

2016
The heart of PD: Lewy body diseases as neurocardiologic disorders.
    Brain research, 2019, 01-01, Volume: 1702

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Catecholamines; Dopamine; Heart; Humans; Lewy Bodies; Lewy Body Disease; Multiple System Atrophy; Myocardium; Neuroimaging; Neurons; Parkinson Disease; Sympathetic Nervous System

2019

Other Studies

15 other study(ies) available for 3,4-dihydroxyphenylacetaldehyde and alpha-synuclein

ArticleYear
Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein.
    Neuroscience letters, 2014, May-21, Volume: 569

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Antioxidants; Ascorbic Acid; Cations, Divalent; Chelating Agents; Copper; Dopamine; Edetic Acid; Humans; Iron; Manganese; PC12 Cells; Phenylethyl Alcohol; Protein Aggregates; Protein Multimerization; Rats

2014
The serotonin aldehyde, 5-HIAL, oligomerizes alpha-synuclein.
    Neuroscience letters, 2015, Mar-17, Volume: 590

    Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; alpha-Synuclein; Animals; Dopamine; Hydroxyindoleacetic Acid; Isoenzymes; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; PC12 Cells; Polymerization; Rats; Serotonin

2015
Oligomerization and Membrane-binding Properties of Covalent Adducts Formed by the Interaction of α-Synuclein with the Toxic Dopamine Metabolite 3,4-Dihydroxyphenylacetaldehyde (DOPAL).
    The Journal of biological chemistry, 2015, Nov-13, Volume: 290, Issue:46

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Animals; Cell Membrane; Dopamine; Dopaminergic Neurons; Humans; Lysine; Membrane Lipids; Oxidation-Reduction; Parkinson Disease; Rats; Schiff Bases; Substantia Nigra

2015
DOPAL is transmissible to and oligomerizes alpha-synuclein in human glial cells.
    Autonomic neuroscience : basic & clinical, 2016, Volume: 194

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Catecholamines; Cell Line; Dose-Response Relationship, Drug; Glioblastoma; Humans; Mutation; Neuroglia; PC12 Cells; Protein Aggregates; Rats; Subcellular Fractions; Time Factors

2016
Toxic Dopamine Metabolite DOPAL Forms an Unexpected Dicatechol Pyrrole Adduct with Lysines of α-Synuclein.
    Angewandte Chemie (International ed. in English), 2016, 06-20, Volume: 55, Issue:26

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Limit of Detection; Pyrroles

2016
DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function.
    Scientific reports, 2017, 01-13, Volume: 7

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Biological Transport; Cell Line; Cell Membrane; Humans; Magnetic Resonance Spectroscopy; Mice; Neurons; Permeability; Protein Aggregates; Protein Aggregation, Pathological; Protein Binding; Protein Multimerization; Synaptic Vesicles; Tandem Mass Spectrometry

2017
Superoxide is the critical driver of DOPAL autoxidation, lysyl adduct formation, and crosslinking of α-synuclein.
    Biochemical and biophysical research communications, 2017, May-27, Volume: 487, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Binding Sites; Cross-Linking Reagents; Enzyme Activation; Lysine; Oxidation-Reduction; Oxygen; Protein Binding; Pyrroles; Reactive Oxygen Species; Superoxide Dismutase

2017
A Systems Model of Parkinson's Disease Using Biochemical Systems Theory.
    Omics : a journal of integrative biology, 2017, Volume: 21, Issue:8

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Biomarkers; Brain; Cell Death; Computer Simulation; Disease Progression; Dopamine; Dopaminergic Neurons; Gene Expression Regulation; Humans; Models, Statistical; Neurofibrillary Tangles; Parkinson Disease; Reactive Oxygen Species; Signal Transduction; Stochastic Processes; Systems Theory; tau Proteins; Ubiquitin-Protein Ligases

2017
Pleiotropic neuropathological and biochemical alterations associated with Myo5a mutation in a rat Model.
    Brain research, 2018, 01-15, Volume: 1679

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Central Nervous System; Disease Models, Animal; Electron Transport Chain Complex Proteins; Heredodegenerative Disorders, Nervous System; Microscopy, Electron, Transmission; Mutation; Myosin Heavy Chains; Myosin Type V; Phosphorylation; Rats; Rats, Mutant Strains; tau Proteins

2018
Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.
    Biochemistry, 2018, 03-06, Volume: 57, Issue:9

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Cross-Linking Reagents; Humans; Isoindoles; Models, Molecular; Neurons; Oxidation-Reduction; Parkinson Disease

2018
Role of Parkinson's Disease-Linked Mutations and N-Terminal Acetylation on the Oligomerization of α-Synuclein Induced by 3,4-Dihydroxyphenylacetaldehyde.
    ACS chemical neuroscience, 2019, 01-16, Volume: 10, Issue:1

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylation; alpha-Synuclein; Dopamine; Dopaminergic Neurons; Humans; Membrane Lipids; Mutation; Oxidation-Reduction; Parkinson Disease; Protein Multimerization; Protein Processing, Post-Translational

2019
Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy.
    European journal of pharmacology, 2019, Feb-15, Volume: 845

    Topics: 3,4-Dihydroxyphenylacetic Acid; Aldehydes; alpha-Synuclein; Animals; Indans; Neuroprotective Agents; Parkinson Disease; PC12 Cells; Rats

2019
3,4-Dihydroxyphenylacetaldehyde Is More Efficient than Dopamine in Oligomerizing and Quinonizing
    The Journal of pharmacology and experimental therapeutics, 2020, Volume: 372, Issue:2

    Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; alpha-Synuclein; Antioxidants; Cell Line; Copper; Dopamine; Humans; Monoamine Oxidase; Monophenol Monooxygenase; Oligodendroglia; Oxidation-Reduction; Parkinson Disease; Protein Binding; Protein Conformation; Tolcapone

2020
Parkinson-like early autonomic dysfunction induced by vagal application of DOPAL in rats.
    CNS neuroscience & therapeutics, 2021, Volume: 27, Issue:5

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Animals; Autonomic Nervous System Diseases; Baroreflex; Blood Pressure; Electrocardiography; Hypotension, Orthostatic; Male; Mitochondria, Heart; Myocardium; Myocytes, Cardiac; Nodose Ganglion; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; Vagus Nerve

2021
Structural Features and Toxicity of α-Synuclein Oligomers Grown in the Presence of DOPAC.
    International journal of molecular sciences, 2021, Jun-02, Volume: 22, Issue:11

    Topics: 3,4-Dihydroxyphenylacetic Acid; alpha-Synuclein; Amyloid; Cell Proliferation; Dopamine; Dopaminergic Neurons; Humans; Oxidative Stress; Parkinson Disease; Phenylethyl Alcohol; Protein Aggregation, Pathological; Protein Multimerization

2021